**Author details**

Horacio Bach Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

\*Address all correspondence to: hbach@mail.ubc.ca

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**15**

*A New Era without Antibiotics*

Medizin. 1884;**2**:185-189

2017;**15**(1):65

**References**

*DOI: http://dx.doi.org/10.5772/intechopen.83691*

[1] Gram HC. Über die isolierte Färbung der Schizomyceten in Schnitt- und Trockenpräparaten. Fortschritte der

hospitals, 2002. Public Health Reports.

[11] Peleg AY, Hooper DC. Hospital-

Gram-negative bacteria. The New England Journal of Medicine. 2010;**362**(19):1804-1813

2007;**122**(2):160-166

acquired infections due to

[12] Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews. Drug

Discovery. 2004;**3**(8):711-716

[13] Mullard A. 2010 FDA drug approvals. Nature Reviews. Drug

[14] Infectious Diseases Society of America. The 10 ב20 initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clinical Infectious Diseases.

[15] Piddock LJ. The crisis of no new antibiotics—What is the way forward? The Lancet Infectious Diseases.

[16] Wright GD. Something old, something new: Revisiting natural products in antibiotic drug discovery. Canadian Journal of Microbiology.

[17] Gould IM, Bal AM. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence. 2013;**4**(2):185-191

[18] Song CH, Han J-W. Patent cliff and strategic switch: Exploring strategic design possibilities in the pharmaceutical industry. Springerplus.

[19] Spink WW, Ferris V. Quantitative

action of penicillin inhibitor from penicillin-resistant strains of staphylococci. Science. 1945;**102**(2644):221-223

Discovery. 2011;**10**:82-85

2010;**50**(8):1081-1083

2012;**12**(3):249-253

2014;**60**(3):147-154

2016;**5**(1):692

[2] Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: Understanding the mechanisms behind antibacterial activity. Journal of Nanobiotechnology.

[3] Pray L. Antibiotic resistance, mutation rates and MRSA. Nature

[4] Kondrashov A. Genetics: The rate of human mutation. Nature.

[5] Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection.

[6] Nikaido H. Multidrug resistance in bacteria. Annual Review of Biochemistry. 2009;**78**:119-146

[7] Read AF, Woods RJ. Antibiotic resistance management. Evolution, Medicine, and Public Health.

[8] Rossolini GM, Arena F, Pecile P, Pollini S. Update on the antibiotic resistance crisis. Current Opinion in Pharmacology. 2014;**18**:56-60

[10] Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health careassociated infections and deaths in U.S.

Education. 2008;**1**(1):30

2012;**488**(7412):467-468

2012;**18**(3):268-281

2014;**2014**(1):147

[9] Gross M. Antibiotics in crisis. Current Biology. 2013;**23**(24):R1063-R1065

*A New Era without Antibiotics DOI: http://dx.doi.org/10.5772/intechopen.83691*
